DE69610483T2 - In kunstlisches Rekombinantes Substrat rAGG-1 und nativem Aggrecan zum Studium der proteolytischen Wirkung von 'Aggrecanase' in Zellkultursystemen - Google Patents

In kunstlisches Rekombinantes Substrat rAGG-1 und nativem Aggrecan zum Studium der proteolytischen Wirkung von 'Aggrecanase' in Zellkultursystemen

Info

Publication number
DE69610483T2
DE69610483T2 DE69610483T DE69610483T DE69610483T2 DE 69610483 T2 DE69610483 T2 DE 69610483T2 DE 69610483 T DE69610483 T DE 69610483T DE 69610483 T DE69610483 T DE 69610483T DE 69610483 T2 DE69610483 T2 DE 69610483T2
Authority
DE
Germany
Prior art keywords
aggrecanase
recombinant substrate
ragg
studying
human igg1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69610483T
Other languages
English (en)
Other versions
DE69610483D1 (de
Inventor
Eckart Bartnik
Bernd Eidenmueller
Frank Buettner
Bruce Caterson
Clare Hughes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of DE69610483D1 publication Critical patent/DE69610483D1/de
Application granted granted Critical
Publication of DE69610483T2 publication Critical patent/DE69610483T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DE69610483T 1996-01-18 1996-12-27 In kunstlisches Rekombinantes Substrat rAGG-1 und nativem Aggrecan zum Studium der proteolytischen Wirkung von 'Aggrecanase' in Zellkultursystemen Expired - Lifetime DE69610483T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96100682 1996-01-18

Publications (2)

Publication Number Publication Date
DE69610483D1 DE69610483D1 (de) 2000-11-02
DE69610483T2 true DE69610483T2 (de) 2001-06-13

Family

ID=8222415

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69610483T Expired - Lifetime DE69610483T2 (de) 1996-01-18 1996-12-27 In kunstlisches Rekombinantes Substrat rAGG-1 und nativem Aggrecan zum Studium der proteolytischen Wirkung von 'Aggrecanase' in Zellkultursystemen

Country Status (11)

Country Link
US (2) US5872209A (de)
EP (1) EP0785274B1 (de)
JP (1) JP3973253B2 (de)
AT (1) ATE196652T1 (de)
AU (1) AU713828B2 (de)
CA (1) CA2195385C (de)
DE (1) DE69610483T2 (de)
DK (1) DK0785274T3 (de)
ES (1) ES2150064T3 (de)
GR (1) GR3034649T3 (de)
PT (1) PT785274E (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0785274T3 (da) * 1996-01-18 2000-12-27 Aventis Pharma Gmbh Kunstigt rekombinant substrat (rAGG-1) og nativ aggrecan til undersøgelse af den proteolytiske aktivitet af "aggrecanase" i
US6451575B1 (en) 1997-07-25 2002-09-17 Bristol-Myers Squibb Pharma Company Aggrecan degrading metallo proteases
AU8513098A (en) * 1998-07-24 2000-02-14 Du Pont Pharmaceuticals Company Assays and peptide substrate for determining aggrecan degrading metallo proteaseactivity
US6649377B1 (en) 1999-05-10 2003-11-18 Syntex (U.S.A.) Llc Human aggrecanase and nucleic acid compositions encoding the same
CA2460539C (en) 2001-09-15 2013-10-29 Rush-Presbyterian-St. Luke's Medical Center Stratified cartilage tissue and methods to engineer same
US20030165473A1 (en) * 2001-11-09 2003-09-04 Rush-Presbyterian-St. Luke's Medical Center Engineered intervertebral disc tissue
DE102004029470A1 (de) * 2004-06-18 2006-01-05 InViTek Gesellschaft für Biotechnik & Biodesign mbH Verfahren zur Bestimmung von Aggrekanase-Aktivitäten
DE102005005972A1 (de) 2005-02-09 2006-08-17 Sanofi-Aventis Deutschland Gmbh Verwendung von Thiopeptoliden zur Aktivitätsbestimmung von ADAM-T8 Proteasen
JP2011528916A (ja) * 2008-07-28 2011-12-01 ドリット アラド 病原体、疾患若しくは医学的状態又はそのバイオマーカーの検出のための方法及び組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427954A (en) * 1992-04-29 1995-06-27 Shriner's Hospitals For Crippled Children Compositions and methods for detection and treatment of human osteoarthritis
GB9310978D0 (en) * 1993-05-27 1993-07-14 Zeneca Ltd Compounds
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
SE9500023L (sv) * 1994-05-17 1995-11-18 Beki Ab Sätt att detektera cancer
DK0785274T3 (da) * 1996-01-18 2000-12-27 Aventis Pharma Gmbh Kunstigt rekombinant substrat (rAGG-1) og nativ aggrecan til undersøgelse af den proteolytiske aktivitet af "aggrecanase" i

Also Published As

Publication number Publication date
PT785274E (pt) 2001-01-31
DE69610483D1 (de) 2000-11-02
US5872209A (en) 1999-02-16
US6180334B1 (en) 2001-01-30
AU1019997A (en) 1997-07-24
EP0785274B1 (de) 2000-09-27
DK0785274T3 (da) 2000-12-27
CA2195385A1 (en) 1997-07-19
JPH09191889A (ja) 1997-07-29
GR3034649T3 (en) 2001-01-31
EP0785274A1 (de) 1997-07-23
ES2150064T3 (es) 2000-11-16
CA2195385C (en) 2010-07-27
ATE196652T1 (de) 2000-10-15
AU713828B2 (en) 1999-12-09
JP3973253B2 (ja) 2007-09-12

Similar Documents

Publication Publication Date Title
Gross et al. Antineutrophil cytoplasmic autoantibodies, autoantigens, and systemic vasculitis
DK1064303T3 (da) Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne
LU91237I2 (fr) Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance)
HUP0101136A2 (hu) Fehérjeexpresszió baculovírus-vektort alkalmazó expressziós rendszerben
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
DK160948C (da) Middel, testmateriale og fremgangsmaade til bestemmelse af tilstedevaerelsen af leukocyter, esterase eller protease
DE69610483T2 (de) In kunstlisches Rekombinantes Substrat rAGG-1 und nativem Aggrecan zum Studium der proteolytischen Wirkung von 'Aggrecanase' in Zellkultursystemen
ATE270330T1 (de) Alpha untereinheit des humanen beta-2 integrins
SE9500023L (sv) Sätt att detektera cancer
ATE258310T1 (de) Testverfahren für collagenpeptid
DE69518450T2 (de) Test zum Nachweis von Proteinen in einer biologischen Probe
DE69231567T2 (de) Screeningverfahren von morphogenischen Proteinen
EA199900138A1 (ru) Обнаружение активности гепараназы млекопитающих и очистка гепараназы млекопитающих
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
DE69504959T2 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
DE69716305T2 (de) Peptidereagenz zum nachweis von humanem cytomegalovirus (cmv)
ATE136931T1 (de) Verfahren zum screenen einer expressions-cdna- klonbank zur auffindung von polynukleotiden
DE59710668D1 (de) Monoklonale antikörper gegen das epitop ypydvpdya, verfahren zu deren herstellung und ihre verwendung
YU73494A (sh) Postupak za dobijanje proteina
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
DK1572931T3 (da) Fremgangsmåder og sammensætninger til modulering og påvisning af WISP-aktivitet
MX9700469A (es) Un substrato recombinante artificial (ragg 1) y agrecano natural para estudiar la actividad proteolitica de "agrecanasa" en sistemas de cultivos celulares.
SE9803398D0 (sv) "New use"
ATE442383T1 (de) Mutierte bcl-2 proteine und verwendung davon

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, 65929 FRANKFURT,